^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

KD-025 CAR T-cells

i
Other names: KD-025 CAR T-cells, NKG2D-based CAR T-cells, KD-025, KD025, KD 025
Associations
Company:
KAEDI
Drug class:
NKG2D-targeted CAR-T immunotherapy
Associations
1m
Thermosensitive hyaluronic acid-manganese-capsaicin complex nanogel improving NKG2D/CAR-T melanoma treatment through adjusting tumor microenvironment. (PubMed, Int J Biol Macromol)
The results of immunohistochemistry and immunofluorescence assays showed that the combined HA-Mn-CAP Gel and NKG2D/CAR-T significantly increased the proliferation and infiltration of T cells, especially for CD8+ cells. Therefore, the new promising strategy of increasing the target ligand expression and adjusting TME before administering CAR-T cells is suitable for treating solid tumors.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • NKG2D (killer cell lectin like receptor K1) • ULBP2 (UL16 Binding Protein 2)
|
KD-025 CAR T-cells
4ms
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors (clinicaltrials.gov)
P=N/A, N=9, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
New trial • Metastases
|
KD-025 CAR T-cells
over1year
Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer. (PubMed, Cancer Sci)
In sum, our study reveals the role of DKK1 in remodeling GC TIME and regulating the expression levels of NKG2DLs in GC. We also provide a promising treatment strategy of combining DKK1 inhibition with NKG2D-CAR-T cell therapy, which could bring new breakthroughs for GC immunotherapy.
Journal • Combination therapy • CAR T-Cell Therapy • IO biomarker
|
DKK1 (dickkopf WNT signaling pathway inhibitor 1) • NKG2D (killer cell lectin like receptor K1)
|
KD-025 CAR T-cells
over2years
Tandem CAR-T cells targeting CLDN18.2 and NKG2DL for treatment of gastric cancer. (ASCO 2022)
Our work construct a tandem CAR molecule targeting two tumor-associated antigens, NKG2DL and CLDN18.2, and found that Tan-CAR-T cells(KD-496)distinctly recognize the antigens and exhibited superior antitumor effect. KD-496 CAR-T cells potently respond to GC and more efficient tumor elimination than single CAR such as KD-025 and KD-182 CAR-T cells in PDX model with no obvious safety issue. The results support future clinical trial of KD-496 CAR in patients with GC, where the need for effective treatment is great.
CAR T-Cell Therapy • IO biomarker
|
CLDN18 (Claudin 18) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CLDN8 (Claudin 8) • NKG2D (killer cell lectin like receptor K1)
|
CLDN18.2 expression
|
KD-025 CAR T-cells • KD-182
almost3years
Clinical • New P1 trial • CAR T-Cell Therapy
|
NKG2D (killer cell lectin like receptor K1)
|
KD-025 CAR T-cells
4years
[VIRTUAL] Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment (ASH 2020)
Prior therapies received by the responders included ibrutinib (6 pts), ruxolitinib (5 pts), and KD025 (3 pts); 3 of the responding pts had received all of these. These data demonstrate that axatilimab is clinically active with acceptable safety profile and responses observed in heavily pretreated pts with active cGVHD. Enrollment continues in the Phase 1 study at 3 mg/kg q4w and Phase 2 study at a dose of 1 mg/kg q2w.
P1 data
|
CD14 (CD14 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
|
Imbruvica (ibrutinib) • Jakafi (ruxolitinib) • KD-025 CAR T-cells • Niktimvo (axatilimab-csfr)
over4years
[VIRTUAL] Eradication of medulloblastoma by NKG2D-specific CAR T-cells. (ASCO 2020)
Our work with the KD-025 contributes to the growing body of research committed to discovering a novel therapy for MB. NKG2D ligands are highly expressed on human MB samples. KD-025 potently respond to MB and eliminate tumor in a xenograft mouse model with no obvious safety issues.
CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • NKG2D (killer cell lectin like receptor K1)
|
KD-025 CAR T-cells